The Dawn of a Cure? Early HIV Treatment Shows Promise for Children
A groundbreaking study presented at the Conference on Retroviruses and Opportunistic Infections suggests that very early antiretroviral therapy (ART) may allow some children born with HIV to control the virus even after stopping treatment. This offers a glimmer of hope in the ongoing quest for an HIV cure, particularly for those infected at or near birth.
The ‘Mississippi Baby’ and Beyond: A History of Hope
The possibility of achieving remission in early-treated infants first gained attention with the case of the “Mississippi baby” in 2014. This child, who began ART within days of birth, maintained undetectable viral loads for years after discontinuing treatment. While that case remains unique, it sparked intense research into the potential benefits of extremely early intervention.
The Ucwaningo Lwabantwana Cohort Study: Unlocking the Potential
Inspired by the Mississippi baby case, researchers established the Ucwaningo Lwabantwana Cohort Study in KwaZulu-Natal, South Africa – a region with a high prevalence of HIV. The study followed 330 mother-infant pairs, with all children initiating ART within the first 21 days of life. This early start aims to minimize the size of the viral reservoir, making it easier for the immune system to control the virus later on.
Recent Findings: One-Third Achieve Viral Control
The latest research, involving 19 children who began ART within 21 days of birth, revealed that one-third (six children) maintained undetectable viral loads for at least 12 weeks after stopping treatment. While some experienced viral rebound later, the initial period of control is significantly longer than typically observed in adults.
“When we position this in the context of other studies like this in adults, 96% of adults experience viral rebound before 12 weeks of treatment interruption, which means only 4% of adults have no detectable virus in the blood after being off treatment for 12 weeks or more,” explained Gabriela Z. L. Cromhout, MD, MSc, DTM&H. “This shows us that a much larger proportion of very early treated children born with HIV are able to control HIV without medication owing to early treatment alone.”
Why Children May Hold the Key to a Cure
Researchers believe children may have a greater potential for HIV cure than adults due to several factors. Early ART initiation leads to a smaller viral reservoir, and the immune systems of young children remain strong and capable of fighting opportunistic infections. This combination creates a more favorable environment for viral control and potential eradication.
Implications for Future Treatment Strategies
These findings reinforce the importance of early HIV diagnosis and treatment for infants. The “Treat All” approach, recommended by the WHO in 2015, emphasizes universal HIV screening and immediate treatment for those who test positive. However, ensuring access to timely testing and ART remains a challenge, particularly in resource-limited settings.
Further research is needed to identify the factors that predict which children will achieve sustained viral control after stopping treatment. Understanding these mechanisms could lead to the development of more targeted and effective strategies for HIV cure.
FAQ
Q: What is ART?
A: ART stands for antiretroviral therapy. It’s a combination of medications used to treat HIV infection.
Q: What does “undetectable viral load” mean?
A: It means the amount of HIV in the blood is so low that it cannot be detected by standard tests.
Q: Is a cure for HIV possible?
A: While a complete cure remains elusive, these findings suggest that it may be more achievable in children who receive very early treatment.
Q: Where was this study conducted?
A: The study was conducted in KwaZulu-Natal, South Africa, and presented at the Conference on Retroviruses and Opportunistic Infections in Denver.
For more information: Gabriela Z. L. Cromhout, MD, MSc, DTM&H can be reached at pediatrics@healio.com.
Source: Cromhout GZL, et a. Abstract 153. Presented at: Conference on Retroviruses and Opportunistic Infections; Feb. 22-25, 2026; Denver.
Do you have questions about HIV treatment for children? Share your thoughts in the comments below!
Related reading
- Injectable Biomaterial for Post-Stroke Tissue Repair
- New Research on Exosomes Offers Shingles Pain Treatments
- Tennessee Schools Shift to Virtual Learning and Early Dismissal Due to Extreme Heat (news-usa.today)
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)